Acelrx Pharmaceuticals Incorporated (NASDAQ:ACRX) Short Interest Decreased By 14.29%

January 10, 2018 - By reb123z

 Acelrx Pharmaceuticals Incorporated (NASDAQ:ACRX) Short Interest Decreased By 14.29%

Investors sentiment decreased to 0.7 in Q3 2017. Its down 0.05, from 0.75 in 2017Q2. It worsened, as 12 investors sold AcelRx Pharmaceuticals, Inc. shares while 15 reduced holdings. 8 funds opened positions while 11 raised stakes. 6.65 million shares or 37.02% less from 10.56 million shares in 2017Q2 were reported.
Comml Bank Of New York Mellon Corporation owns 67,961 shares. Geode Management Limited Liability Corp accumulated 215,834 shares. 787 were accumulated by Federated Invsts Pa. Williams Jones & holds 22,800 shares or 0% of its portfolio. Raymond James And Associates has 0% invested in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) for 46,000 shares. Vanguard Grp Inc accumulated 1.38M shares. Meeder Asset Mgmt holds 0% or 1,120 shares. One Trading L P invested in 0% or 60,379 shares. Bridgeway Management accumulated 319,150 shares. 11,988 are owned by Cambridge Advisors. 648 are owned by Goldman Sachs Group. Two Sigma Secs Lc stated it has 0.01% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Susquehanna Group Incorporated Llp reported 226,288 shares or 0% of all its holdings. Retail Bank Of America Corp De invested in 0% or 3,300 shares. Perceptive Advisors Limited Company holds 0.22% of its portfolio in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) for 1.24 million shares.

Since October 2, 2017, it had 0 insider buys, and 1 sale for $53,752 activity.

The stock of Acelrx Pharmaceuticals Incorporated (NASDAQ:ACRX) registered a decrease of 14.29% in short interest. ACRX’s total short interest was 5.55M shares in January as published by FINRA. Its down 14.29% from 6.48M shares, reported previously. With 682,600 shares average volume, it will take short sellers 8 days to cover their ACRX’s short positions. The short interest to Acelrx Pharmaceuticals Incorporated’s float is 20.81%.

The stock decreased 2.27% or $0.05 during the last trading session, reaching $2.15. About 53,823 shares traded. AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) has declined 14.24% since January 10, 2017 and is downtrending. It has underperformed by 30.94% the S&P500.

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company has market cap of $108.23 million. The Company’s lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet, which is in Phase III clinical trial for the treatment of moderate-to-severe acute pain. It currently has negative earnings. The companyÂ’s late-stage investigational product candidate is Zalviso, a pre-programmed and patient-controlled analgesia device that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Ratings Coverage

Among 8 analysts covering AcelRx Pharmaceuticals (NASDAQ:ACRX), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. AcelRx Pharmaceuticals had 20 analyst reports since August 4, 2015 according to SRatingsIntel. Jefferies downgraded the stock to “Hold” rating in Friday, October 13 report. Piper Jaffray maintained the stock with “Hold” rating in Thursday, October 12 report. The firm earned “Hold” rating on Tuesday, August 4 by Cowen & Co. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, September 2. H.C. Wainwright maintained AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) rating on Tuesday, May 3. H.C. Wainwright has “Buy” rating and $7 target. Cowen & Co maintained the stock with “Hold” rating in Tuesday, August 1 report. The firm has “Hold” rating given on Tuesday, July 25 by Piper Jaffray. The stock of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) earned “Buy” rating by TH Capital on Monday, October 5. Jefferies maintained the stock with “Hold” rating in Tuesday, November 14 report. Jefferies maintained it with “Buy” rating and $700 target in Friday, July 14 report.

More notable recent AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) news were published by: Fool.com which released: “Why AcelRx Pharmaceuticals Inc Got Cut in Half Today” on October 12, 2017, also Prnewswire.com with their article: “AcelRx Pharmaceuticals Reports Second Quarter 2017 Financial Results and …” published on August 01, 2017, Seekingalpha.com published: “AcelRx: Device Error Rate And Opioid Crisis In Perspective” on August 04, 2017. More interesting news about AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) were released by: Seekingalpha.com and their article: “AcelRX: A Misunderstood Diamond In The Rough” published on August 22, 2017 as well as Fool.com‘s news article titled: “Why AcelRx Pharmaceuticals Inc Jumped Higher Today” with publication date: October 02, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.